Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000692544 | SCV000820371 | pathogenic | PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome | 2023-01-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PURA protein in which other variant(s) (p.Tyr261*) have been determined to be pathogenic (PMID: 25439098). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 571407). This premature translational stop signal has been observed in individual(s) with clinical features of early infantile epileptic encephalopathy (Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg4*) in the PURA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 319 amino acid(s) of the PURA protein. |
Baylor Genetics | RCV000692544 | SCV004041108 | pathogenic | PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome | 2023-01-15 | criteria provided, single submitter | clinical testing | |
Génétique des Maladies du Développement, |
RCV000692544 | SCV001499896 | pathogenic | PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome | no assertion criteria provided | clinical testing |